Abrams Darryl, Brodie Daniel
Division of Pulmonary, Allergy and Critical Care, Columbia University College of Physicians and Surgeons, New York City, New York, USA.
Curr Opin Crit Care. 2016 Feb;22(1):73-9. doi: 10.1097/MCC.0000000000000273.
Despite advances in extracorporeal membrane oxygenation (ECMO) technology, much is unknown about the optimal management strategies for patients receiving extracorporeal support. There is a growing body of literature investigating patient selection and outcomes, mechanical ventilation approaches, anticoagulation, pharmacokinetics, early mobilization, and the role of ECMO transport among others.
Nonrandomized data suggest a survival advantage from ECMO compared with conventional management in acute respiratory distress syndrome, with mechanical ventilation practices varying widely across centers. A randomized controlled trial is currently ongoing with standardized ventilation approaches in both arms. Low-level anticoagulation appears to be well tolerated, and ECMO circuitry appears to affect the pharmacokinetics of certain drugs. Pilot and matched cohort studies suggest that extracorporeal carbon dioxide removal is effective in preventing intubation in chronic obstructive pulmonary disease, with larger randomized studies being planned. ECMO may be successful in bridging selected patients to lung transplantation, with early mobilization serving as a well tolerated and effective means of optimizing these patients. Regionalization of ECMO may maximize outcomes and is facilitated by the development of ECMO transport teams.
Recently published data highlight the evolving management strategies of patients receiving extracorporeal support and help identify those patients most appropriate for ECMO and extracorporeal carbon dioxide removal. More data will ultimately be needed to develop an evidence-based consensus.
尽管体外膜肺氧合(ECMO)技术取得了进展,但对于接受体外支持的患者的最佳管理策略仍知之甚少。越来越多的文献在研究患者选择与预后、机械通气方法、抗凝、药代动力学、早期活动以及ECMO转运的作用等方面。
非随机数据表明,在急性呼吸窘迫综合征中,与传统管理相比,ECMO具有生存优势,各中心的机械通气实践差异很大。目前正在进行一项双臂采用标准化通气方法的随机对照试验。低水平抗凝似乎耐受性良好,并且ECMO回路似乎会影响某些药物的药代动力学。试点研究和匹配队列研究表明,体外二氧化碳清除在预防慢性阻塞性肺疾病患者插管方面是有效的,目前正在计划开展更大规模的随机研究。ECMO可能成功地将选定患者过渡到肺移植,早期活动是优化这些患者的一种耐受性良好且有效的方法。ECMO的区域化可能会使预后最大化,并且ECMO转运团队的发展有助于实现这一点。
最近发表的数据突出了接受体外支持患者不断演变的管理策略,并有助于确定最适合ECMO和体外二氧化碳清除的患者。最终需要更多数据来形成基于证据的共识。